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Background: Abdominal aortic aneurysm (AAA) is characterized by vascular remodeling with increased
inﬁltration of inﬂammatory cells and apoptosis/modulation of vascular smooth muscle cells (SMCs).
Imatinib is a selective inhibitor of several tyrosine kinases, including PDGF receptors, Abl, and c-kit. The
objective of this study was to characterize the potential protective role of imatinib on AAA development
and the molecular mechanisms involved.
Methods: Male ApoE/ mice were infused with angiotensin (Ang) II (1000 ng/kg/min) for 4 weeks to
induce AAA or saline as controls. Daily treatment with 10 mg/kg imatinib, or tap water as control, was
provided via gavage for 4 weeks.
Results: Treatment with imatinib was found to decrease the aortic diameter and vessel wall thickness,
mediated by multiple effects. Imatinib treatment in AngII infused mice resulted in a reduced cellular
inﬁltration of CD3ε positive T lymphocytes by 86% and reduced gene expression of mast cell chymase by
50% compared with AngII infused mice lacking imatinib. Gene expression analysis of SMC marker SM22a
demonstrated an increase by 48% together with a more intact medial layer after treatment with imatinib
as evaluated with SM22a immunostaining.
Conclusion: Present ﬁndings highlight the importance of tyrosine kinase pathways in the development of
AAA. Our results show, that imatinib treatment inhibits essential mast cell, T lymphocyte and SMC
mediated processes in experimental AAA. Thus, our results support the idea that tyrosine kinase in-
hibitors may be useful in the treatment of pathological vascular inﬂammation and remodeling in con-
ditions like AAA.
© 2016 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-
ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Abdominal aortic aneurysm (AAA) is a chronic inﬂammatory
disease resulting in vascular remodeling. AAA is associated with
inﬁltration of leukocytes, such as T lymphocytes, mast cells, neu-
trophils and macrophages, which produce various matrix-
degrading proteases. Phenotypic modulation and increased, Department of Medical and
ces, Link€oping University, SE-
).
Ireland Ltd. This is an open accessapoptosis of smooth muscle cells (SMCs) and degradation of the
extracellular matrix (ECM) also occurs [1e4]. In normal blood
vessels, the predominant vascular SMC phenotype is the contractile
phenotype that regulates vessel diameter and blood ﬂow [5].
Phenotypic modulation of SMCs is critical in regulating vascular
function in health and disease. The switch from the contractile to
the migratory and proliferative phenotype e known as the dedif-
ferentiated synthetic phenotype e takes place during tissue repair
in response to vascular injury. In this phenotype, SMCs increase
their rate of cell proliferation and migration in response to growth
factors and/or chemoattractant and this process plays a critical role
in maintaining the integrity of the vessel [6]. SMCs are one of thearticle under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
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strength to the aortic wall. Collagen synthesis increases during the
early stages of aneurysm formation suggesting a repair process
while in later stages of AAA collagen degradation, due to protease
produced by inﬁltrated leukocytes, exceeds its synthesis which
may eventually lead to rupture of the aortic wall [7].
Imatinib is a small molecule with potent and selective inhibitory
activity against several tyrosine kinases, including; Abl, c-Kit and
platelet-derived growth factor receptor (PDGFR) -a and -b [8,9].
Imatinib has good oral bioavailability and has become the standard
of care for patients with chronic myelogenous leukemia and
gastrointestinal stromal tumors, because it inhibits the growth of
malignant cells [8]. However, the mechanism of action of imatinib
may be broader than originally expected, and might also be tar-
geting non-malignant disorders such as pulmonary arterial hy-
pertension, hyperlipidemia, hypercholesterolemia and
atherosclerosis [10e12]. Furthermore, imatinib may inhibit T lym-
phocytes proliferation and activation [13] as well as inhibit mast
cell activation by inducing apoptosis [14]. Both cells play an evident
role in the development and progression of AAA [15,16].
Given the fact that imatinib may inhibit key pathways in for-
mation of AAA, i.e. T lymphocytes, mast cells, SMC proliferation and
PDGF signaling, the objectives of this study was to characterize the
potential protective role of imatinib on AAA development and the
molecular mechanisms involved.
2. Material and methods
2.1. Human subjects
This study included 12 patients in whom preoperative
computed tomography had demonstrated an eccentric intra-
luminal thrombus and who were scheduled for elective surgery for
infrarenal AAA at Karolinska University Hospital, Stockholm, Swe-
den. During surgery the intraluminal thrombus was removed from
the aortic vessel wall. The intima/media and adventitia of AAAwere
separated by adventicectomy. Patients were included after
informed, written, and signed consent, and the studies were per-
formed with approval from the local ethical committee at Kar-
olinska Institutet in Stockholm, Sweden.
Control ascending aorta samples (layers not separated) for RNA
studies were obtained from 8 organ donors, and infrarenal control
aortas for histology were collected from 14 medicolegal autopsies
without clinical or macroscopic signs of aortic atherosclerosis or
aneurysm. Autopsies of control aorta samples were performed in
the Department of Forensic Medicine, University of Helsinki. The
sections were immediately ﬁxed in 4% formaldehyde for light mi-
croscopy or snap frozen in liquid nitrogen for RNA isolation. The use
of organ donor and autopsy tissues was approved by The National
Authority for Medicolegal Affairs of Finland.
2.2. AngII-induced AAA in mice
AngII-induced aneurysm is an inﬂammation-driven model that
is frequently used to experimentally induce AAA [17]. Male hy-
percholesterolemic ApoE/ mice were obtained from Taconic
(Bomholt, Denmark). At eight weeks of age, AAA was induced by
chronic infusion of 1000 ng/kg/min AngII (Cat.no.9525, Sigma
Aldrich, St. Louis, USA) via mini-osmotic pumps (Model 1004, Alzet,
CA, USA) as described previously [18]. A group of ApoE/ mice
were infused with 0.9% NaCl and were used as control mice. In
order to study the signiﬁcance of tyrosine kinase signaling in AAA
development, imatinib, a tyrosine kinase inhibitor was adminis-
trated. Oral gavage treatment with 10 mg/kg imatinib mesylate
(STI571, Novartis, Stockholm, Sweden) was given daily throughoutthe study starting two days before implantation of the mini-
osmotic pumps. Administration of tap water was given orally to
ApoE/mice which served as control mice. Mice were divided into
four groups, two groups obtained mini-osmotic pumps releasing
AngII and two groups obtained mini-osmotic pumps releasing 0.9%
NaCl. From each exposure one group either obtained 10 mg/kg
imatinib or tap water orally. Groups were divided as follow; NaCl
and tap water (n ¼ 7), AngII and tap water (n ¼ 9), NaCl and ima-
tinib (n ¼ 9) and AngII and imatinib (n ¼ 8). Standard Chow diet
and water was allowed ad libitum throughout the whole study and
mice were monitored daily for signs of discomfort. After 28 days,
mice were sacriﬁced. The aorta was removed and ﬁxated in RNA-
later for 24 h thereafter frozen in 70 C for gene expression
analysis and plasma was taken for cholesterol measurements
which were performed using Total cholesterol þ HDL þ Glucose
Panel, CardioChec (Medistore, Stockholm, Sweden). The study was
approved by the local ethical committee 2014-09-04, 68-14 in
Link€oping, Sweden.
2.3. Quantitative real-time PCR
Human and mouse aortas were homogenized with trizol and
chloroform in Lysing Matrix D tubes (MP Biomedicals, Illkirch,
France) using FastPrep. Total RNA from human and mice aortas
were isolated with RNeasy mini kit (Qiagen, Hilden, Germany) and
reversely transcribed with random primers and Superscript II
(Invitrogen, Carlsbad, USA). cDNA (human 0.5 mg; mouse 0.21 mg)
was ampliﬁed by RT-PCR with 1 TaqMan Universal PCR Master-
mix (Applied Biosystems, Foster City, USA) on a ABI 7700 Real-time
PCR Sequence Detector, run in duplicates as previously described
[18]. All probes were obtained from Applied Biosystems
(Supplementary table I), and the results were normalized to
expression levels of human RPLP0 or mouse Gapdh.
2.4. Immunohistochemistry
Parafﬁn-embedded human and mouse abdominal aortas were
sectioned (5 mm) and rehydrated in several changes of ethanol and
Tissue-Clear® (Sakura Finetek, Leiden, The Netherlands). Endoge-
nous peroxidase activity was quenched by treatment with 3%
hydrogen peroxide for 5 min followed by incubation in 5% blocking
bovine serum albumin solution. Sections were then incubated with
primary antibodies against mouse CD3ε (1 mg/ml, Cat. no. BS3476,
Bioworld Technology, St Louis Park, USA), SM22a (0.6 mg/ml, Cat.
no. ab14106, Abcam, Cambridge, UK) and PDGFR-b (phospho-
Tyr751, 10 mg/ml, Cat. no. LS-C178098, LSBio, Seattle, USA) or hu-
man PDGF-D (0.5 mg/ml, Cat. no. AF1159) and PDGFR-b (1 mg/ml,
Cat. no. AF385) (RnD Systems, Minneapolis, USA), Von Willebrand
factor (0.2 mg/ml, Cat. no. A0082, Dako, Glostrup, Denmark), CD68
(0.1 mg/ml, Cat. no.NCL-CD68-KP1, Leica Microsystems, Newcastle,
UK) and a-actin (0.6 mg/ml, Cat. no. A5228, clone 1A4, Sigma-
Aldrich) at 4 C overnight followed by secondary biotinylated
goat anti-rabbit IgG or goat anti-mouse IgG (Dako) antibody.
Isotype-matched immunoglobulin was used in the same concen-
tration as corresponding primary antibody in order to assess the
level of non-speciﬁc binding (Cat. no. ab27472, Abcam). Avidin-
biotin peroxidase complexes (Dako) were added followed by
visualization with 3,30-diaminobenzidine tetrahydrochloride
(Dako). All sections were counterstained with Mayer's hematoxylin
(Histolab Products, G€oteborg, Sweden). Sections were studied un-
der light microscopy (Zeiss, Jena, Germany). Quantiﬁcation of CD3ε
positive cells in aortas was deﬁned as number per mm2. A scoring
system from 1 to 4 was used for quantiﬁcation of phosphor-speciﬁc
PDGFR-b expression, with 1 deﬁned as no or low expression, 2 as
expression in aortic media, 3 as expression in aortic media and
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data is expressed in arbitrary units (AU). Quantiﬁcations were
performed blinded.
2.5. Masson Trichrome staining
Parafﬁn-embedded sections (5 mm) were rehydrated in several
changes of ethanol and Tissue-Clear® (Sakura Finetek). Sections
were then incubated in Bouin's solution (Sigma-Aldrich) at room
temperature overnight, counterstainedwithWeigert's hematoxylin
working solution (HistoLab) for 10 min following by staining with
the Masson Trichrome kit (Sigma-Aldrich) containing Biebrich's
Scarlet-acid Fuchsin solution for 15 min, Phosphomolybdic-
Phosphotungstic acid solution for 10 min and Aniline Blue solu-
tion for 5 min. Sections were differentiated in 1% acetic acid,
washed in distilled water, dehydrated in tissue clear and several
changes of ethanol before mounted with mounting medium. Sec-
tions were studied under light microscopy. Collagen displayed blue
and cytoplasm and muscle ﬁbers stained red. Quantiﬁcation of
collagen was performed blinded. A scoring system from 1 to 4 was
used with 1 deﬁned as low amount of collagen in all layers of the
aorta, 2 as low amount of collagen in aorta media or in aorta
adventitia, 3 as high amount of collagen in aorta media or in aorta
adventitia, and 4 as high amount of collagen in all layers of the
aorta. Aortic diameter was measured as the leading edge to leading
edge measurement calculated from the inner luminal diameter and
outer adventitial diameter based on respective circumference and
vessel wall thickness. An aneurysm was set as a 1.5-fold enlarge-
ment of the vessel wall. As there occurs vascular remodeling, aortic
vessel wall thickness was also measured.
2.6. Toluidine blue staining
Parafﬁn-embedded sections (5 mm) were deparafﬁnized and
hydrated in several changes of ethanol and Tissue-Clear® (Sakura
Finetek). Sections were then stained in toluidine blue working so-
lution with pH 2.3 for 3 min followed by three washes in distilled
water, dehydrated in tissue clear and several changes of ethanol
before mounted with mounting medium. Sections were studied
under light microscopy. Quantiﬁcation of the mast cells, stained
dark purple, was performed blinded and normalized to aortic
vessel wall area (mm2) and total numbers per aorta since theywere
few in numbers.
2.7. Verhoeff's Van Gieson staining
Parafﬁn-embedded mice aortas were stained with Verhoeff's
hematoxylin for 1 h, differentiated in 2% ferric chloride for 2 min,
and counterstained with Van Gieson's stain for 5 min to identify
elastic ﬁbers in the aortic tissue stained black. Quantiﬁcation of
elastin was performed blinded using a scoring system from 1 to 4
was used with 1 deﬁned as intact elastin, 2 as low degradation of
elastin, 3 as intermediate degradation of elastin, and 4 as high
degradation of elastin.
2.8. Statistical analysis
The statistical analysis was performed with the IMB SPSS Sta-
tistics 22. All measurements are shown as median and standard
deviations. Two-group comparisons of quantitative data were
performed using the non-parametric ManneWhitney U test or the
parametric Student T-test, and correlation between genes was
performed using Pearson's Rank Correlation. Multiple test correc-
tion was performed using Holm-Bonferroni. P-values < 0.05 were
considered statistically signiﬁcant where * indicates P < 0.05, **indicates P < 0.01 and *** indicates P < 0.001. Quantitative results
represented in bar as mean values and error bars as standard
deviation.3. Results
3.1. Imatinib inhibits vascular remodeling in AngII infused mice
To elucidate the potential role of imatinib and corresponding
pathway in aneurysmal formation, mice were administrated ima-
tinib in the drinking water under infusion of AngII by mini-osmotic
pumps. Infusion of AngII for four weeks led to a signiﬁcant increase
in the aortic diameter (0.47 ± 0.09 mm; P < 0.01) and vessel wall
thickness by 3.2-fold (0.08 ± 0.03 mm; P < 0.001) and displayed an
aneurysmal phenotype compared with saline-infused control
aortas (0.34 ± 0.04 mm; Fig. 1A, B and C). Imatinib inhibited growth
of the aortic diameter by 50% when compared with AngII infused
mice lacking imatinib treatment (0.40 ± 0.07 mm; P < 0.05, Fig. 1A
and B) and displayed a less aneurysmal phenotype. Imatinib was
further found to decrease the vessel wall thickness by 50% as
compared with mice administrated with only AngII
(0.04 ± 0.01 mm; P < 0.001, Fig. 1A and C). After AngII infusion, 9/13
(69%) of the mice administrated with tap water developed an
aneurysm but only 2/9 (22%) of the imatinib administrated mice
developed such lesions (P < 0.05). Aneurysmal aortas displayed a
more disorganized medial layer and extracellular matrix compo-
nents such as increased production of collagen and cellular
composition compared with imatinib treated mice. Number of
ruptures was 17% in AngII infused mice administrated with tap
water while in mice administrated with imatinib rupture did not
occur. Histological staining and scoring of elastin in aorta media
demonstrated a variation in the degree of elastin degradation in all
mice infused with AngII compared to saline-infused control aortas
when stained with Verhoeff's van Gieson (Supplementary Fig. 1).
However there were no differences in elastin degradation between
imatinib administrated mice and tap water administrated mice
after infusion with AngII.
Further, levels of total cholesterol was decreased (P ¼ 0.01) in
AngII infused mice administrated with imatinib compared to its
control at the same time HDL levels were increased
(Supplementary Table 2).3.2. Imatinib inhibit inﬁltration of T-cells and mast cell in the aortic
wall
Cellular inﬁltration of inﬂammatory leukocytes is one of the
hallmarks of vascular remodeling leading to aneurysmal develop-
ment. Administration of imatinib in AngII infusedmice resulted in a
reduction of CD3ε positive T lymphocytes (P < 0.05) to normal
levels as compared with mice infused with only AngII (Fig. 2A and
B) as demonstrated with immunohistological staining. However,
imatinib did not change the expression of CD3e on gene level
(Fig. 2C).
Histological staining of mast cells showed few mast cells in
general (Fig. 3A) with a decreased number of mast cells per aorta in
imatinib treated AngII mice (P < 0.05, Fig. 3A and C). However we
could not observe any effects of imatinib on the number of mast
cells/mm2 in the vessel wall (Fig. 3A and B). Gene expression
analysis on aortas of imatinib treated AngII infused mice demon-
strated decreased expression ofmast cell chymase (P < 0.05) by 50%
as compared with AngII infused mice that were not treated with
imatinib (Fig. 3D).
Fig. 1. Abdominal aortic aneurysm development. (A) show representative images of the histological analyses performed by Masson Trichrome staining. Measurements of the edge
to edge leading aortic diameter (B) and the aortic wall thickness (C). Horizontal lines represent median of each group. Statistical signiﬁcance was established using non-parametric
Mann Whitney U test where * indicates P < 0.05, ** indicates P < 0.01 and *** indicates P < 0.001 after adjusting for multiple testing. Control n ¼ 10; AngII n ¼ 13; Imatinib n ¼ 9;
AngII þ Imatinib n ¼ 9. The images are taken with 10 and 40 magniﬁcation. Scale bar represents 50 mm.
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To further determine the effects of imatinib in vascular inﬂam-
mation and matrix degeneration, changes in expression levels of
proinﬂammatory cytokines, chemokines and proteases were
measured in the aortas by semi-quantitative real-time PCR. Overall,
the increased expression of AngII tended to decrease in the imatinib
treatedmice (Supplementary Fig. 2). Chemokine (CeCmotif) ligand
5 (CCL5), a T lymphocytes chemokine, was signiﬁcantly higher
expressed in both AngII groups as comparedwith their controls and
imatinib tended to reduce the increase by 50% compared to AngII
infused mice without imatinib. AngII infusion lacking imatinib
treatment signiﬁcantly increased gene expression of TNF-a by 15-
fold (P < 0.001) and IL-6 by 76-fold (P < 0.001), an increase that
was inhibited and not signiﬁcantly increased in imatinib treated
animals.3.4. Imatinib preserves SMCs
We next examined the impact of imatinib on SMCs content and
gene expression. Immunohistochemical staining demonstrated
that SMCs in mice treated with imatinib after AngII infusion werelocalized to the intima/media as observed in control mice while
aneurysmal AngII infused mice administrated with tap water
demonstrated an intimal/medial thickening by SMCs (Fig. 4A).With
quantitative real-time PCR imatinib administratedmicewere found
to express SM22a to levels equal to control mice and 48% higher
(P < 0.01) as compared with AngII infused mice (Fig. 4B). Further-
more, staining of SM22a revealed that the reduced amount of
SM22a seen on gene level in AngII infusedmice administrated with
tap water not only is caused by loss of SMCs due to apoptosis, but
might also suggest a phenotypical switch of contractile SMC
phenotype to the more proliferative and migratory synthetic SMC
phenotype [19].
SMCs are one of the main producers of collagen to the vessel
wall. We identiﬁed an increased compensatory production of
collagen in mice infused with AngII lacking imatinib compared
with control aortas (P < 0.01). AngII infused mice administrated
with imatinib, which displayed a more normal aorta, did not in-
crease the production of collagen as compared with AngII infused
mice lacking imatinib (P < 0.05, Fig. 4C).
Fig. 2. Effect of Imatinib on T-cells. (A) immunohistochemical staining of CD3ε in the different mice groups stained in brown. (B) Quantiﬁcation of CD3ε positive cells in aortas per
mm2. (C) Gene expression of the lymphocyte marker CD3e relative to Gapdh as measured by qRT-PCR. Results are presented in box plot using median with the 25th and 75th
percentiles. T-bars indicate outliers extend to 1.5 times the height of the box. “C” outlier greater than 3 times the interquartile range. Statistical signiﬁcance was established using
non-parametric Mann Whitney U test where * indicates P < 0.05 and ** indicates P < 0.01. The images is taken with 40 magniﬁcation. Scale bar represents 50 mm. . (For
interpretation of the references to colour in this ﬁgure legend, the reader is referred to the web version of this article.)
Fig. 3. Toluidine blue staining of mast cell in the aortas of each treatment group (A). Positive cells are stained in dark purple and are indicated with red arrows. Quantiﬁcation of
mast cells in the aortas per mm2 (B) and the total number of cells per aorta (C). The mRNA expression ofmast cell tryptase (D) relative to Gapdh as measured by qRT-PCR. Results are
presented in box plot using median with the 25th and 75th percentiles. T-bars indicate outliers extend to 1.5 times the height of the box. “B” Outlier greater than 1.5 times the
interquartile range. “C” outlier greater than 3 times the interquartile range. Statistical signiﬁcance was established using non-parametric Mann Whitney U test where * indicates
P < 0.05, ** indicates P < 0.01 and *** indicates P < 0.001. The images is taken with 40magniﬁcation. Scale bar represents 50 mm. (For interpretation of the references to colour in
this ﬁgure legend, the reader is referred to the web version of this article.)
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Effects of imatinib in vascular integrity are mediated through
several tyrosine kinases, also including PDGF receptors. Geneexpression of PDGFR-b tended to decrease after imatinib treatment,
but no signiﬁcant differences were observed between AngII infused
aortas and saline-infused control aortas (Fig. 5A). The expression
and localization of the receptors as well as most of their ligands
Fig. 4. Immunohistochemical staining of SM22a in the different treatments; control, AngII, Imatinib, and AngII þ Imatinib (A). Immunohistochemical staining of positive cells are
stained in brown. The mRNA expression of smooth muscle cell marker SM22a (B) relative to Gapdh as measured by qRT-PCR. Results are presented in box plot using median with the
25th and 75th percentiles. T-bars indicate outliers extend to 1.5 times the height of the box. “B” Outlier greater than 1.5 times the interquartile range. “C” Outlier greater than 3
times the interquartile range. (C) Histological quantiﬁcation of collagen performed on Masson trichrome stained aortas. Statistical signiﬁcance was established using non-parametric
Mann Whitney U test where * indicates P < 0.05 and ** indicates P < 0.01. The images is taken with 40 magniﬁcation. Scale bar represent 50 mm. (For interpretation of the
references to colour in this ﬁgure legend, the reader is referred to the web version of this article.)
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have investigated the latest discoveredmember, PDGF-D, in AAA. In
addition, gene expression analysis of PDGF-D showed decrease by
52% in AngII mice compared to control mice (P < 0.001, Fig. 5B). At
the same time, treatment with imatinibwas found to normalize the
PDGF-D gene expression to levels observed in control mice and as
compared to AngII infusedmice (P < 0.05). The mRNA expression of
PDGF-D and PDGFR-b correlated strongly to SM22a expression
(r ¼ 0.87; P < 0.001 and r ¼ 0.80; P < 0.01). Immunohistochemical
analysis of phosphorylated PDGFR-b revealed a heterogeneous
expression localized dominantly to SMCs (Fig. 5C). Imatinib
signiﬁcantly (P < 0.05) reduced the expression in the aortas of AngII
infused mice (2.5 ± 0.5 AU) compared to AngII infused mice not
given the drug (3.3 ± 0.9 AU).
While expression of PDGFR-bwas unaffected inmurine AAA, the
expression of PDGFR-b was signiﬁcantly lower in all layers in hu-
man aortas with AAA as compared with non-aneurysmal control
aortas (Fig. 5D). In agreement with what was observed in mouse
AAA, expression of PDGF-Dwas also reduced in all layers of the AAA
samples with a 68% decrease in the aneurysmal wall tissues
compared to non-aneurysmal control aortas (Fig. 5F). The mRNA
expression of PDGF-D correlated strongly to PDGFR-b expression
(r¼ 0.84; P < 0.001). Immunohistochemical analysis of PDGF-D and
PDGFR-b conﬁrmed the gene expression pattern on a protein level.
In non-aneurysmal control aortas, the staining of both PDGF-D and
its receptor PDGFR-b were, in general, strong and mainly localized
to SMCs, luminal endothelial cells, and neovessels in the adventitia.
Staining of PDGF-D and PDGFR-b, however, was weaker and
localized to SMCs and neovessels in the aneurysmal adventitia
(Fig. 5E and G) and, to some extent, to macrophages (data not
shown).4. Discussion
By identifying key cellular and molecular mechanisms that
promote aneurysmal expansion we could get a better insight intothe disease progression and thereby identify new therapeutic tar-
gets used for future treatment. Inhibition of key features using
imatinib may represent a novel therapeutic target in cardiovascular
disease such as AAA. This is particularly of interest because imatinib
has been shown to have minimal side effects when used in cancer
therapy in humans [20]. Overall, imatinib is a well-tolerated drug
and clinical side effects mainly appear as moderate. Some patients
experience nausea, diarrhea, edema, weight loss, muscle cramps,
and headache. In some rare occasions patients might develop more
sever pathological evens such as cardiac toxicities which are
associated with long-term treatment [21]. The majority of patients
who develop cardiotoxicity, heart failure or myocardial infarction
are generally older (>65 years) with existing or pre-existing risk
factors for cardiac disease. Other cardiac complications associated
with imatinib are hypo/hypertension, tachycardia and pericarditis
however the prevalence appears to be less than 1% [22,23]. These
side effects are also dose dependent and could be reduced by
lowering the dosage. One beneﬁcial side effect is that imatinib
lowers plasma LDL cholesterol, and increases HDL, which we also
could observe in our animal model. Imatinib is currently a Food and
Drug Administration (FDA) approved drug for treatment of chronic
myelogenous leukemia and gastrointestinal stromal tumors due to
its inhibitory effect on growth of malignant cells, but recent studies
have suggested that imatinib might be useful not only against tu-
mors, as it has also shown vascular protective properties [24].
It is well-established that there is an increased inﬁltration of
inﬂammatory cells into the aortic wall due to artery injury,
including AAA. Furthermore, it is known that tyrosine kinases play
a prominent role in T lymphocyte receptor signaling [13] and mast
cell survival [14], suggesting that imatinib may interfere with this
process. With histological staining of mouse aortas, we demon-
strated that treatment with imatinib decreased the amount of CD3ε
positive T lymphocytes and mast cells signiﬁcantly in the arterial
wall of mice infused with AngII, compared with aneurysmal mice
aortas without imatinib treatment. Our ﬁndings were shared by a
recent study published by Seggewiss and co-workers where they
Fig. 5. Gene expression of mouse PDGFR-b (A) and PDGF-D (B) relative to Gapdh and immunohistochemical staining of phospho-PDGFR-b in mice aortas (C). Gene expression of
human PDGFR-b (D) and PDGF-D (F) relative to RPLP0 in non-aneurysmal control aortas and AAA samples from the intima/media or adventitia (n ¼ 8 or 9 in each group) as
determined by real-time PCR. Immunohistochemical staining of PDGFR-b (E) and PDGF-D (G) in the tunica intima, media, and adventitia of AAA samples and non-aneurysmal
control aortas, stained in brown. Scale bar represents 50 mm. Results are presented in box plot using median with the 25th and 75th percentiles. T-bars indicate outliers extend
to 1.5 times the height of the box. *P < 0.05, **P < 0.01 vs. non-aneurysmal aortas (Mann-Whitney U test). “B” Outlier greater than 1.5 times the interquartile range. “C” Outlier
greater than 3 times the interquartile range. Abbreviations: adv, adventitia; med, intima/media. (For interpretation of the references to colour in this ﬁgure legend, the reader is
referred to the web version of this article.)
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in response to different kinds of mitogens, by direct inhibition of
TCR signaling through inhibition of the tyrosine kinases such as Abl
which is known to be involved in T lymphocyte activation [13,25].
They showed that both the overall percentage of all T lymphocytes
undergoing cell division and the average number of divisions
completed were signiﬁcantly reduced. Furthermore, imatinib does
not induce apoptosis in T lymphocytes and the reduced prolifera-
tion observed is therefore not contributed by increased apoptosis
[13]. We further observed that imatinib decreased the expression of
CCL5, a chemokine important for the recruitment of T lymphocytes
to the aneurysmal wall. Several studies have also shown the
importance and involvement of mast cells in many aspects of AAA
formation [15,26]. Sun and coworkers demonstrated increasedaccumulation of mast cells within the AAA lesion after inducing
AAA with elastase perfusion. These cells were shown to produce
cytokines IL-6 and IFN-g which in turn affected matrix degrading
proteases such as MMPs and cathepsins. We observed that imatinib
treatment inhibited the induction of IL-6 in our animal model
which could to some degree depend on the inhibition of mast cells
and T lymphocytes within the vessel wall but also to loss and
phenotypic changes of SMCs. They also suggested that mast cell-
derived IL-6 and IFN-g might regulate SMC apoptosis [15]. Mast
cells are known to express c-kit which is essential for its survival.
Further, Juurikivi and coworkers treated cultured mast cell with
imatinib which resulted in an induced mast cell apoptosis through
inhibition of c-kit [14]. This is in agreement with our ﬁndings
where we demonstrated that imatinib reduces the number of mast
E. Vorkapic et al. / Atherosclerosis 249 (2016) 101e109108cells per aorta. Fewer mast cells contribute less to the inﬂammation
that potentially could lead to fewer inﬂammatory cells such as T
lymphocytes, having an essential role on aneurysmal progression.
Furthermore, since mast cells may modulate SMC responses in
experimental aneurysm making it even more critical to consider
this aspect.
The chronic inﬂammation occurring during disease develop-
ment activity leads to phenotypic modulation and apoptosis of
vascular SMCs and degradation of the ECM network, including
collagen. Our in vivo study on aneurysmal mice also demonstrated a
decrease in the expression level of the SMC marker SM22a which
could indicate SMC differentiation from contractile to synthetic
SMC and/or apoptosis which is in agreement with other studies
[27]. With our immunostaining we could demonstrate a more
disorganized aortic wall with migrating SMC. Nevertheless, we
report that administration of imatinib during AngII infusion
blocked the repression of SM22a as well as having a more normal
SMC morphology reﬂecting an aortic wall resembling the normal
aorta. In response to injury SMC actively produces collagen, which
is in agreement with the compensatory production of collagens
found in human AAA [7]. We could also observe this effect in our
aneurysmal in vivomodel whereas an increased amount of collagen
was demonstrated after infusionwith AngII in order to stabilize the
vessel wall, which was inhibited by imatinib since the disease
progression was dampened. Lassila and coworkers demonstrated a
minimal expression of C-abl kinase in the vasculature indicating
that the effects seen with imatinib administration in vivo has very
low or no effect via this protein [12]. Contradictory, studies has
demonstrated c-kit as highly present in dedifferentiated vascular
SMCs in the aortic wall suggesting that effects of imatinib partially
could be mediated via c-kit inhibition [28,29]. These ﬁndings
resulted in a decreased aortic diameter as well as thickness indi-
cating the importance of imatinib on vascular remodeling and
progression of AAA through regulation of T lymphocyte and mast
cell inﬁltrationwithin the aneurysmal aorta as well as SMC content
and collagen production.
Further evidence suggests that effects of imatinib in vascular
integrity and atherosclerosis are primarily via its ability to control
PDGF receptor activation [9]. By forming a complex with PDGFR-b,
Boucher and co-workers could demonstrate that low density lipo-
protein receptor-related protein 1 (LRP-1) has a pivotal role in
protecting vessel wall integrity and preventing atherosclerosis and
thereby controlling its activation. They also demonstrated that
treatment with imatinib blocked activation of LRP-1einduced
phosphorylation of PDGFR-b and reduced the size and area of the
atherosclerotic lesions [9]. In our experiments, PDGFR-b seem to be
differently regulated in human andmurine AAA, which complicates
the interpretation of its role. However, we could demonstrate a
reduced expression of phosphorylated PDGFR-b in aortas of ima-
tinib treated animals.
The PDGFs exert their cellular function by activating two tyro-
sine kinase receptors, PDGFR-a and PDGFR-b and has been associ-
ated with several human disorders. [30] The expression of PDGF-A,
-B and -C, and the receptors, PDGFR-a and -b, has been demon-
strated in both human and murine AAA and especially by the SMCs
[30e32]. Prior to the present study, the expression and localization
of PDGF-D in AAA disease is unknown. In human aortas PDGF-Dwas
the most dramatically changed family member and its expression
was decreased signiﬁcantly in the aneurysmal wall of both human
and mice. We found that PDGF-D was predominantly localized to
medial SMCs and endothelial cells, and to some extent in macro-
phages, which is in agreement with what is observed in athero-
sclerotic aortas [33,34]. The expression of PDGFR-b is found to be
particularly high in aortic media localized and expressed by aortic
SMC [32,34,35]. Expression of PDGF-D and PDGFR-b was stronglycorrelated to SMC marker SM22a in human samples. In AAA, not
only does phenotypical differentiation of SMC occur [4], but
apoptosis is another important hallmark in the disease progression.
The reduced expression of PDGF-D and PDGFR-b in the aortic wall
could, to some part, be an outcome of SMC loss due to apoptosis.
Upregulated PDGF-D expression in imatinib treated mice may
reﬂect a more preserved SMC content.
5. Conclusion
Taken together, our ﬁndings identify imatinib as a novel po-
tential drug in aneurysmal treatment by affecting several key fea-
tures important in aneurysmal formation. Through inhibition of T
lymphocytes and mast cells recruitment and by preserving the
medial layer of SMC, imatinib could play a part in attenuating
pathological vascular inﬂammation and remodeling and thereby
AAA development. Our data supports the fact that blockage of
tyrosine kinase signaling using imatinib may be extended as
treatment of cardiovascular diseases, such as AAA, due to its po-
tential to impair features associated with AAA development. In
order to investigate potential biological signiﬁcance and implica-
tions clinical trials are needed.
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